Merck Sharp + Dohme Corp.

Merck + Co., Inc.

Hong Li

Cameron James Smith

Yi-Heng Chen

Peter J Sinclair

Sherman Tim Waddell

Zhijian Lu

Amjad Ali

Tao Yu

Thomas H Graham

Christopher Francis Thompson

John M Sanders

John A McCauley

Izzat Tiedje Raheem

XiaoXia Qian

Petr Vachal

Yonglian Zhang

Guizhen Dong

Debra L Ondeyka

Julianne A Hunt

Alan Whitehead

Andrew William Stamford

Paul J Coleman

Emma R Parmee

John S Wai

Jianming Bao

Yong Zhang

Shawn P Walsh

Harold B Wood

Guoqing Li

Subharekha Raghavan

Jianmin Fu

Dongfang Meng

Wanying Sun

Qiaolin Deng

Richard Berger

Manuel De Lera Ruiz

Linda Brockunier

Shouwu Miao

Xibin Liao

Ramzi Farah Sweis

Jiang Chang

Jiayi Xu

John E Stelmach

James M Apgar

Dann LeRoy Parker, Jr

Ting Zhang

Robert Kevin Orr

Sriram Tyagarajan

Bart Harper

Jian Guo

Gayle E Taylor

Tianying Jian

Jay A Grobler

Joie Garfunkle

Meng Yang

Rui Zhang

Kake Zhao

Nazia Quraishi

Keith Rosauer

Ronald Dale Ferguson, Ii

Jonathan A Groeper

Olga Ornoski

Louis-Charles Campeau

Gang Ji

Jane Yang Wu

Sunita V Dewnani

Florida Kallashi

Xiaoqing Han

Falong Jiang

Adrian A Dowst

Joann M Napolitano

Xiaoxia Qian

Samantha E Adamson

John A Mccauley

Linda L Brockunier

Raphelle Berger

John Stelmach

Olga A Ornoski

The present invention relates to Substituted Quinolizine Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1 is as defined herein. The present invention also relates to compositions comprising at least one Substituted Quinolizine Derivative, and methods of using the Substituted Quinolizine Derivatives for treating or preventing HIV infection in a subject. 

Substituted quinolizine derivatives useful as HIV integrase inhibitors

The present invention provides a compound of Formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing unstable angina, refractory angina, myocardial infarction, transient ischemic attacks, atrial fibrillation, thrombotic stroke, embolic stroke, deep vein thrombosis, disseminated intravascular coagulation, ocular build up of fibrin, and reocclusion or restenosis of recanalized vessels. The compounds are selective Factor IXa inhibitors. 

Factor IXa inhibitors

The present invention relates to Substituted Quinolizine Derivatives of Formula (I): and pharmaceutically acceptable salts or prodrug thereof, wherein X, Y, R, R, R, R, R, Rand Rare as defined herein. The present invention also relates to compositions comprising at least one Substituted Quinolizine Derivative, and methods of using the Substituted Quinolizine Derivatives for treating or preventing HIV infection in a subject.

The present invention relates to Phosphate Substituted Quinolizine Derivatives of Formula (I): and pharmaceutically acceptable salts or prodrug thereof, wherein X, Y, R, R, R, R, R, Rand Rare as defined herein. The present invention also relates to compositions comprising at least one Phosphate Substituted Quinolizine Derivative, and methods of using the Phosphate Substituted Quinolizine Derivatives for treating or preventing HIV infection in a subject. 

Phosphate substituted quinolizine derivatives useful as HIV integrase inhibitors

The present invention relates to Substituted Quinolizine Derivatives of Formula (I): and pharmaceutically acceptable salts or prodrug thereof, wherein X, Y, R, R, R, R, R, Rand Rare as defined herein. The present invention also relates to compositions comprising at least one Substituted Quinolizine Derivative, and methods of using the Substituted Quinolizine Derivatives for treating or preventing HIV infection in a subject. 

Compounds having the structure of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and may be useful for raising HDL-cholesterol and reducing LDL-cholesterol in human patients and for treating or preventing atherosclerosis. The chemical compounds that are disclosed cholesterol ester transfer protein (CETP) and are expected to have utility in raising HDL-C, lowering LDL-C, and in the treatment and prevention of atherosclerosis. 

Spirocyclic CETP inhibitors

A compound of Formula (I): or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate ('cGMP') and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula (I) or a pharmaceutically acceptable salt thereof. 

Soluble guanylate cyclase activators

Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compound of Formula I, Ais a substituted phenyl group or indanyl group. Formula (I). 

Cyclic amine substituted oxazolidinone CETP inhibitor

Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. The compounds have 3 cyclic groups connected by single bonds, as for example triphenyl, which are attached directly to the ring of formula I or attached at the position B. 

1,3-oxazolidin -2-one derivatives useful as CETP inhibitors

1,3-oxazolidin-2-one derivatives useful as CETP inhibitors

Compounds having the structure of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula (I), B is a cyclic group other than phenyl, and B has a cyclic substituent at a position that is ortho to the position at which B is connected to the remainder of the structure of Formula (I). The 5-membered ring of Formula (I) has a second cyclic substituent in addition to B. 

CETP inhibitors

Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis: In the compounds of Formula I, B or Ris a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalkyl substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalkyl substituent connected directly to the ring or attached to the ring through a &#x2014;CH&#x2014;.

Growing community of inventors

Edison, NJ, United States of America

Hong Li